Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reactive oxygen and nitrogen species (RONS) and electrophilic xenobiotics are a broad class of highly reactive molecules that induce oxidative and electrophilic stress in biological systems (Sies, H., 2015, PMID: 25588755). RONS, including superoxide, hydroxyl radicals, and nitric oxide, are generated endogenously during mitochondrial respiration and immune activation, while electrophilic xenobiotics are exogenous compounds that react with cellular nucleophiles such as DNA and protein thiols (Halliwell & Gutteridge, 2015). At physiological levels, these species function as critical signaling molecules in processes like vasodilation and immune defense; however, their overproduction leads to damage of lipids, proteins, and nucleic acids (Forman et al., 2014, PMID: 24561250). This damage is a hallmark of various pathologies, including cancer, neurodegenerative disorders, and chronic inflammation. Pharmacological intervention typically focuses on neutralizing these species using direct scavengers (antioxidants) or indirectly by activating the Nrf2-Keap1 pathway to upregulate endogenous detoxification enzymes (Zhang, D.D., 2010, PMID: 20478357).
Drugs targeting these species generally act through three primary mechanisms: 1) Direct scavenging or neutralization of free radicals and oxidants (e.g., Vitamin C, Edaravone); 2) Induction of the endogenous antioxidant response, primarily via the activation of the Transcription Factor Nrf2, which leads to the expression of phase II detoxification enzymes (e.g., Dimethyl fumarate); and 3) Inhibition of the enzymatic sources of RONS, such as NADPH oxidase or Xanthine oxidase (He et al., 2020, PMID: 32206158).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reactive oxygen and nitrogen species and electrophilic xenobiotics (RONS/Electrophiles).